Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (185)	4/1/2002 9:43:58 AM
From: Arthur Radley	Respond to of 631

Biogen Announces Meeting of FDA Advisory Committee to Review AMEVIVE(R) (Alefacept) For Treatment of Psoriasis CAMBRIDGE, Mass., April 1 /PRNewswire-FirstCall/ -- Biogen, Inc. (Nasdaq: BGEN - news) today announced that the U.S. Food and Drug Administration (FDA) will convene a Dermatologic and Opthalmic Drugs Advisory Committee on May 23, 2002 to review the registrational filing of Biogen's drug AMEVIVE® (alefacept) for the treatment of moderate-to-severe chronic plaque psoriasis.

To: scaram(o)uche who wrote (185)	4/5/2002 9:15:58 AM
From: Arthur Radley	Read Replies (2) \| Respond to of 631

Genentech and XOMA Obtain Results From Xanelim --Efalizumab-- Pharmacokinetic Study SOUTH SAN FRANCISCO & BERKELEY, Calif., Apr 5, 2002 (BW HealthWire) -- Genentech Inc. (NYSE: DNA chart, msgs) and XOMA Ltd. (Nasdaq: XOMA chart, msgs) today announced that a pharmacokinetic study conducted on Xanelim(TM) (efalizumab) comparing XOMA-produced material and Genentech-produced material did not achieve pre-defined statistical definition for comparability. The study suggested that the Genentech material achieved a slightly higher serum concentration than the XOMA material. Genentech and XOMA will work closely with the U.S. Food and Drug Administration (FDA) to determine next steps, but this will probably delay the filing of a Biologics Licensing Application (BLA) with the FDA for Xanelim beyond summer 2002. "Genentech and XOMA are encouraged by the Xanelim safety and efficacy data collected to date," said Susan D. Hellmann, M.D., M.P.H., Genentech's executive vice president, Development and Product Operations and chief medical officer. "We continue to enroll patients into ongoing Xanelim clinical trials, including additional studies to expose more patients to the Xanelim material being produced at Genentech for marketing after approval. Genentech now plans to submit data from an additional ongoing efficacy study using Xanelim material produced at Genentech to the FDA and, contingent upon successful discussions with the FDA, expects to be able to submit data from this efficacy study before the end of 2002." During Phase III Xanelim testing, minor manufacturing modifications were made to allow for large-scale material production. Last year the FDA requested a pharmacokinetic study to confirm the comparability of Xanelim material used in clinical trials, which was primarily produced at XOMA, and Xanelim material produced at Genentech for marketing after product approval. As part of the Xanelim clinical program, the companies had earlier successfully completed a number of internal evaluations, including animal pharmacokinetic studies, which supported comparability of the two materials. Xanelim is a targeted T-cell modulator that is designed to target three key processes in the cascade of events that lead to psoriasis. These targeted processes are: (1) binding of T-cells through interactions with adhesion molecules on the endothelial cell surface; (2) migration of T-cells into the skin; and (3) activation of T-cells, all of which may be linked to the abnormal growth of skin cells and the painful, elevated scaly patches of skin (lesions) typical among psoriasis sufferers